Hypertension 2025: Landmark Trials Every Clinician Should Know

Hypertension remains the leading modifiable risk factor for cardiovascular disease worldwide. Despite the availability of effective medications, blood pressure control rates remain suboptimal, contributing to preventable strokes, myocardial infarctions, heart failure, chronic kidney disease, and premature mortality.

Over the past decade, several landmark clinical trials have reshaped our understanding of optimal blood pressure management. More recently, novel therapeutic approaches—including aldosterone synthase inhibition and RNA interference—have opened exciting possibilities for the future of hypertension care.

This article highlights the most influential evidence-based hypertension trials that continue to guide modern clinical practice.

1. SPRINT Trial (2015): Lower May Be Better

The Systolic Blood Pressure Intervention Trial (SPRINT) fundamentally changed hypertension management by demonstrating that intensive blood pressure control can significantly improve cardiovascular outcomes.

Study Population
Adults aged ≥50 years
High cardiovascular risk
Excluded patients with diabetes and prior stroke
Intervention
Intensive treatment: systolic blood pressure target <120 mmHg
Standard treatment: systolic blood pressure target <140 mmHg
Key Findings
25% reduction in major cardiovascular events
27% reduction in all-cause mortality
Lower rates of heart failure and cardiovascular death
Clinical Takeaway

For appropriately selected high-risk patients, intensive blood pressure control provides meaningful cardiovascular protection, although clinicians should carefully monitor for hypotension, electrolyte abnormalities, and kidney function.

2. STEP Trial (2021): Intensive Therapy in Older Adults

The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial answered an important question: Can older adults safely benefit from lower blood pressure targets?

Study Population

Adults aged 60–80 years with hypertension.

Blood Pressure Targets
Intensive: 110–130 mmHg
Standard: 130–150 mmHg
Major Results
Significant reduction in cardiovascular events
No substantial increase in serious adverse events
Benefits were consistent across patient subgroups
Clinical Pearl

Age alone should not discourage intensive blood pressure control. Healthy older adults can derive considerable cardiovascular benefit when therapy is individualized.

3. SSaSS Trial (2021): A Lifestyle Intervention That Saves Lives

The Salt Substitute and Stroke Study demonstrated that replacing regular salt with potassium-enriched salt significantly reduced cardiovascular events.

Key Findings
Reduced stroke incidence
Lower cardiovascular event rates
Reduced all-cause mortality
Clinical Importance

Simple dietary interventions can have population-level impact. For suitable patients without advanced kidney disease or hyperkalemia, potassium-enriched salt substitutes represent an effective, low-cost strategy for cardiovascular prevention.

4. CLICK Trial (2021): Chlorthalidone Returns to the Spotlight

Patients with advanced chronic kidney disease often have difficult-to-control hypertension, and thiazide diuretics were historically considered less effective in this population.

The CLICK trial challenged this belief.

Study Population

Stage 4 chronic kidney disease with poorly controlled hypertension.

Intervention

Chlorthalidone versus placebo.

Results
Significant reduction in systolic blood pressure
Effective even in advanced CKD
Acceptable safety profile with appropriate monitoring
Clinical Message

Chlorthalidone should be reconsidered as an effective therapeutic option in resistant hypertension associated with advanced CKD.

5. PATHWAY-2: The Resistant Hypertension Game Changer

Although published several years earlier, PATHWAY-2 remains the definitive study for resistant hypertension.

Major Finding

Spironolactone was superior to alternative fourth-line antihypertensive agents.

Practical Recommendation

Patients with resistant hypertension should be evaluated for secondary causes, but in most cases spironolactone remains the preferred fourth-line therapy unless contraindicated.

6. BaxHTN Phase III (2025): A New Drug Class Emerges

One of the most exciting recent developments is baxdrostat, an aldosterone synthase inhibitor.

Why Is It Important?

Unlike mineralocorticoid receptor antagonists, baxdrostat reduces aldosterone production at its source.

Phase III Results
Significant reduction in systolic blood pressure
Successful achievement of primary and secondary endpoints
Favorable safety profile
Future Perspective

Pending regulatory approval, baxdrostat may become an important addition to the treatment of resistant hypertension.

7. KARDIA Program: RNA Interference for Hypertension

Perhaps the most innovative approach currently under investigation is zilebesiran, a small interfering RNA (siRNA) therapy targeting angiotensinogen.

Potential Advantages
Long-lasting blood pressure reduction
Injection every three to six months
Improved medication adherence
Sustained antihypertensive effect

Although cardiovascular outcome studies are ongoing, this therapy may transform hypertension management for patients struggling with long-term adherence.

What Do Current Guidelines Recommend?

The evidence from these landmark trials supports a comprehensive approach to hypertension management.

Lifestyle First

Every patient should receive counseling on:

DASH diet
Weight reduction
Regular physical activity
Sodium restriction
Moderation of alcohol intake
Smoking cessation
First-Line Medications

Current recommendations continue to favor:

ACE inhibitors or ARBs
Calcium channel blockers
Thiazide-like diuretics (especially chlorthalidone or indapamide)
Resistant Hypertension

When blood pressure remains uncontrolled despite optimal triple therapy:

Confirm adherence
Exclude secondary causes
Add spironolactone when appropriate
Consider emerging therapies as they become available
Key Clinical Pearls

✅ Lower blood pressure targets improve cardiovascular outcomes in appropriately selected high-risk patients.

✅ Intensive blood pressure control can also benefit many older adults.

✅ Lifestyle modification remains one of the most effective interventions available.

✅ Chlorthalidone continues to play an important role, even in advanced CKD.

✅ Spironolactone remains the preferred fourth-line therapy for resistant hypertension.

✅ Novel therapies such as baxdrostat and zilebesiran represent an exciting new era in hypertension treatment.

Final Thoughts

Hypertension management has evolved substantially over the past decade. While foundational studies such as SPRINT, STEP, SSaSS, CLICK, and PATHWAY-2 continue to shape daily clinical practice, emerging therapies like baxdrostat and zilebesiran suggest that the future of hypertension care will extend beyond traditional pharmacology.

For clinicians, the message is clear: combine evidence-based lifestyle interventions with guideline-directed pharmacotherapy, individualize treatment goals, and remain attentive to rapidly evolving therapeutic innovations. Staying current with these landmark trials will help translate research into better cardiovascular outcomes for patients worldwide.